UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
作者信息
Bhoi Sujata, Baliakas Panagiotis, Cortese Diego, Mattsson Mattias, Engvall Marie, Smedby Karin E, Juliusson Gunnar, Sutton Lesley-Ann, Mansouri Larry
机构信息
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden Department of Medical Sciences, Uppsala University, Sweden.
出版信息
Haematologica. 2016 Feb;101(2):e63-5. doi: 10.3324/haematol.2015.136440. Epub 2015 Nov 20.
Abstract
摘要
相似文献
1
UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Haematologica. 2016 Feb;101(2):e63-5. doi: 10.3324/haematol.2015.136440. Epub 2015 Nov 20.
2
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Oncotarget. 2015 Mar 10;6(7):5426-34. doi: 10.18632/oncotarget.3101.
3
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of gene refines prognosis in treatment-naïve chronic lymphocytic leukemia.
Haematologica. 2017 Apr;102(4):e144-e147. doi: 10.3324/haematol.2016.154450. Epub 2016 Dec 7.
4
COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Leuk Lymphoma. 2017 Jan;58(1):70-79. doi: 10.1080/10428194.2016.1180690. Epub 2016 May 17.
5
LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
Eur J Haematol. 2016 Aug;97(2):175-82. doi: 10.1111/ejh.12700. Epub 2015 Dec 17.
6
THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Probl Radiac Med Radiobiol. 2018 Dec;23:283-301. doi: 10.33145/2304-8336-2018-23-283-301.
7
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Clin Cancer Res. 2013 Nov 1;19(21):5890-900. doi: 10.1158/1078-0432.CCR-13-0622. Epub 2013 Sep 13.
8
Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Pol Arch Intern Med. 2017 Apr 28;127(4):238-244. doi: 10.20452/pamw.3998. Epub 2017 Apr 20.
9
Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Exp Oncol. 2019 Mar;41(1):39-45.
10
Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
Clin Chem. 2007 Feb;53(2):204-12. doi: 10.1373/clinchem.2006.076331. Epub 2006 Dec 7.
引用本文的文献
1
The liver proteome of individuals with a natural UGT2B17 complete deficiency.
Sci Rep. 2025 Feb 14;15(1):5458. doi: 10.1038/s41598-025-89160-4.
2
Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells.
BMC Cancer. 2024 Apr 2;24(1):410. doi: 10.1186/s12885-024-12143-7.
3
A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Cells. 2023 May 2;12(9):1295. doi: 10.3390/cells12091295.
4
Association of Inherited Copy Number Variation in and Pseudogenes with Oropharynx Cancer Risk and Outcome.
Genes (Basel). 2022 Dec 19;13(12):2408. doi: 10.3390/genes13122408.
5
The Glycosyltransferase Pathway: An Integrated Analysis of the Cell Metabolome.
Metabolites. 2022 Oct 21;12(10):1006. doi: 10.3390/metabo12101006.
6
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Br J Cancer. 2020 Jul;123(2):240-251. doi: 10.1038/s41416-020-0887-6. Epub 2020 May 18.
7
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
Br J Cancer. 2020 Mar;122(7):1068-1076. doi: 10.1038/s41416-020-0749-2. Epub 2020 Feb 12.
8
Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression.
Br J Cancer. 2020 Apr;122(9):1277-1287. doi: 10.1038/s41416-019-0722-0. Epub 2020 Feb 12.
9
Inactivation of Prostaglandin E as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia.
Front Oncol. 2019 Jul 4;9:606. doi: 10.3389/fonc.2019.00606. eCollection 2019.
10
Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.
Drug Metab Dispos. 2019 May;47(5):444-452. doi: 10.1124/dmd.119.086330. Epub 2019 Feb 28.
本文引用的文献
1
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196. Epub 2014 Jun 19.
2
The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.
Cancer. 2013 Jul 1;119(13):2477-85. doi: 10.1002/cncr.28009. Epub 2013 Apr 10.
3
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.
4
Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
Blood. 2013 Feb 14;121(7):1175-83. doi: 10.1182/blood-2012-08-447359. Epub 2012 Nov 20.
5
NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia.
Leukemia. 2013 Feb;27(2):512-4. doi: 10.1038/leu.2012.307. Epub 2012 Nov 6.
6
RNA-based markers as prognostic factors in chronic lymphocytic leukemia.
Expert Rev Hematol. 2012 Feb;5(1):69-79. doi: 10.1586/ehm.11.80.
7
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
Haematologica. 2011 Aug;96(8):1153-60. doi: 10.3324/haematol.2010.039396. Epub 2011 Apr 20.
8
Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer.
Carcinogenesis. 2010 Sep;31(9):1620-6. doi: 10.1093/carcin/bgq124. Epub 2010 Jun 16.
9
CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia.
Blood. 2001 Mar 15;97(6):1892-4. doi: 10.1182/blood.v97.6.1892.
10
Genomic aberrations and survival in chronic lymphocytic leukemia.
N Engl J Med. 2000 Dec 28;343(26):1910-6. doi: 10.1056/NEJM200012283432602.
Zotero 插件